113 related articles for article (PubMed ID: 38133515)
1. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer.
Ye W; Lv H; Zhang Q; Zhao J; Zhao X; Zhao G; Yan C; Sun F; Zhao Z; Jia X
J Drug Target; 2024 Dec; 32(2):159-171. PubMed ID: 38133515
[No Abstract] [Full Text] [Related]
2. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)
Yuan XX; Duan YF; Luo C; Li L; Yang MJ; Liu TY; Cao ZR; Huang W; Bu X; Yue X; Liu RY
Biochem Pharmacol; 2023 May; 211():115498. PubMed ID: 36913990
[TBL] [Abstract][Full Text] [Related]
5. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
6. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
10. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
[TBL] [Abstract][Full Text] [Related]
11. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
[TBL] [Abstract][Full Text] [Related]
12. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rb
Niu X; Shi Y; Li Q; Chen H; Fan X; Yu Y; Lv C; Lu J
Phytomedicine; 2023 Jul; 115():154776. PubMed ID: 37087793
[TBL] [Abstract][Full Text] [Related]
15. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
[TBL] [Abstract][Full Text] [Related]
16. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
[TBL] [Abstract][Full Text] [Related]
18. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
19. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
Cui Z; Li D; Zhao J; Chen K
Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
[TBL] [Abstract][Full Text] [Related]
20. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
